Drug Profile
Research programme: atherosclerosis therapy - UCB
Alternative Names: NBI-74330Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator UCB
- Class Acetamides; Pyrimidines
- Mechanism of Action CXCR3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in Netherlands (SC, Injection)
- 07 Nov 2007 Pharmacodynamics data from a preclinical study in Atherosclerosis presented at the 80th Scientific Sessions of the American Heart Association (AHA-2007)
- 05 Jan 2005 Celltech Group has been acquired by UCB